SCHEMBL10172837

SCHEMBL10172837

CC(=O)OCCCCS(=O)(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.52
CA2 P00918 3/20 0.41
TSHR P16473 3/20 0.40
CHRM5 P08912 2/20 0.40
CHRM1 P11229 2/20 0.40
CHRM3 P20309 2/20 0.40
PGR P06401 1/20 0.40
CHRM2 P08172 1/20 0.40
CHRM4 P08173 1/20 0.40
HTR1A P08908 1/20 0.40
CHRNB2 P17787 1/20 0.40
TBXA2R P21731 1/20 0.40
CHRNB4 P30926 1/20 0.40
CHRNA3 P32297 1/20 0.40
CHRNA7 P36544 1/20 0.40
CHRNA4 P43681 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
CHRNA10 Q9GZZ6 1/20 0.40
CHRNA9 Q9UGM1 1/20 0.40
LMNA P02545 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11397955 0.98 ALDH1A1 (0.50) ALDH1A1CA2TSHRCHRM5CHRM1
SCHEMBL14615761 0.98 ALDH1A1 (0.50) ALDH1A1CA2TSHRCHRM5CHRM1
SCHEMBL11394476 0.98 ALDH1A1 (0.50) ALDH1A1CA2TSHRCHRM5CHRM1
SCHEMBL1156282 0.93 ALDH1A1 (0.54) ALDH1A1CA2TSHRCHRM5CHRM1
Hydrochloric Acid SCHEMBL6985786 0.91 ALDH1A1 (0.52) ALDH1A1CA2TSHRCHRM5CHRM1
SCHEMBL11240940 0.91 ALDH1A1 (0.52) ALDH1A1CA2TSHRCHRM5CHRM1
SCHEMBL47547 0.84 ALDH1A1 (0.46) ALDH1A1CA2TSHRCHRM5CHRM1
SCHEMBL14052549 0.82 ALDH1A1 (0.44) ALDH1A1CA2TSHRCHRM5CHRM1
SCHEMBL1622071 0.81 ALDH1A1 (0.50) ALDH1A1CA2TSHRCHRM5CHRM1
SCHEMBL1622814 0.81 ALDH1A1 (0.50) ALDH1A1CA2TSHRCHRM5CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260115157-A1 FORMULATIONS CONTAINING ACETAMINOPHEN AND SULFOALKYL ETHER CYCLODEXTRIN CYDEX PHARMACEUTICALS INC (US) 2026-04-30 US disclosed
US-12527755-B2 Formulations containing acetaminophen and sulfoalkyl ether cyclodextrin CYDEX PHARMACEUTICALS, INC. (US) 2026-01-20 US disclosed
US-20240358544-A1 METHOD OF TREATING VISION LOSS IN A HUMAN SUBJECT WITH PHOTOREACTIVE COMPOUNDS KIORA PHARMACEUTICALS PTY LTD (AU) 2024-10-31 US disclosed
US-20230357451-A1 ALKYLATED CYCLODEXTRIN COMPOSITIONS AND PROCESSES FOR PREPARING AND USING THE SAME CYDEX PHARMACEUTICALS INC (US) 2023-11-09 US disclosed
US-11795241-B2 Fractionated alkylated cyclodextrin compositions and processes for preparing and using the same CYDEX PHARMACEUTICALS, INC. (US) 2023-10-24 US disclosed
EP-3183295-B1 FRACTIONATED ALKYLATED CYCLODEXTRIN COMPOSITIONS AND PROCESSES FOR PREPARING AND USING THE SAME CYDEX PHARMACEUTICALS INC (US) 2023-08-02 EP disclosed
US-20230002513-A1 ALKYLATED CYCLODEXTRIN COMPOSITIONS AND PROCESSES FOR PREPARING AND USING THE SAME CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2023-01-05 US disclosed
EP-4083075-A1 MANUFACTURING PROCESS FOR CYCLODEXTRIN DERIVATIVES CyDex Pharmaceuticals, Inc. (US) 2022-11-02 EP disclosed
US-20220332853-A1 MANUFACTURING PROCESS FOR CYCLODEXTRIN DERIVATIVES CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2022-10-20 US disclosed
US-20160139136-A1 RAPID FLUORESCENCE TAGGING OF GLYCANS AND OTHER BIOMOLECULES WITH ENHANCED MS SIGNALS WATERS TECHNOLOGIES CORPORATION (US) 2016-05-19 US disclosed
US-9200098-B2 Radiation-sensitive composition and compound JSR CORPORATION (JP) 2015-12-01 US disclosed
US-9200098-B2 Radiation-sensitive composition and compound JSR CORPORATION (JP) 2015-12-01 US disclosed
US-20120164582-A1 RADIATION-SENSITIVE COMPOSITION AND COMPOUND JSR CORPORATION (JP) 2012-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240358544-A1 METHOD OF TREATING VISION LOSS IN A HUMAN SUBJECT WITH PHOTOREACTIVE COMPOUNDS PDE6C, ALDH1A2, PDE6D ALDH1A1 572/4885CA2 982/4885TSHR 769/4885
US-20260115157-A1 FORMULATIONS CONTAINING ACETAMINOPHEN AND SULFOALKYL ETHER CYCLODEXTRIN CYP2C8, CYP3A43, SULT2A1 ALDH1A1 2123/4885CA2 769/4885TSHR 1670/4885
US-11795241-B2 Fractionated alkylated cyclodextrin compositions and processes for preparing and using the same AGPS, DDOST, ALG1 ALDH1A1 4018/4885CA2 2294/4885TSHR 4344/4885
US-12527755-B2 Formulations containing acetaminophen and sulfoalkyl ether cyclodextrin TPMT, GSTP1, ALB ALDH1A1 1546/4885CA2 917/4885TSHR 2799/4885
US-20160139136-A1 RAPID FLUORESCENCE TAGGING OF GLYCANS AND OTHER BIOMOLECULES WITH ENHANCED MS SIGNALS FUT5, FUT6, CSGALNACT1 ALDH1A1 4000/4885CA2 4542/4885TSHR 2074/4885
US-20220332853-A1 MANUFACTURING PROCESS FOR CYCLODEXTRIN DERIVATIVES DCXR, AGL, OSTC ALDH1A1 2508/4885CA2 3978/4885TSHR 4583/4885
US-20120164582-A1 RADIATION-SENSITIVE COMPOSITION AND COMPOUND RAD51, RER1, ATP6AP1 ALDH1A1 1300/4885CA2 123/4885TSHR 1556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.